A N -piperidin-4-yl derivative having the general Formula I wherein W is C(O)NH or NH(CO); Y is CHR 3 or a bond; X is N, CH, CF or CR 8 ; A is a (hetero)aromatic group selected from R 1 is H, halogen, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy or halo(C 1-4 )alkyloxy; R 2 is H, halogen, di(C 1-4 )alkylamino, (C 1-4 )alkyl, (C 2-4 )alkenyl, (C 2-4 )alkynyl, halo(C 1-4 )alkyl or (C 1-6 )alkyloxy, optionally substituted with one or more halogens, hydroxy or (C 1-4 )alkyloxy; or R 2 is OCH 2 R 7 ; R 3 is H, (C 1-3 )alkyl or COOR 8 ; R 4 is H, halogen or (C 1-3 )alkyl; or R 4 forms together with R 3 and the carbon atoms to which they are bonded a (C 3-5 )CyCloalkyl goup; R 5 is, halogen, (C 1-4 )alkyl, halo(C 1-4 )alkyl, hydroxy(C 1-4 )alkyl, CN, COOH, CONR 9 ,R 10 , pyridyl or a 5-membered heteroaryl group comprising 1, 2 or 3 nitrogen atoms and optionally an oxygen or a sulfur atom; R 6 is H, hydroxy or halogen; or R 6 forms together with R 5 and the carbon atoms to which they are bonded a fused 5-membered heteroaryl group comprising 1 or 2 nitrogen atoms and optionally an oxygen or a sulfur atom; R 7 is vinyl, ethynyl, cyano, (C 3-6 )cycloalkyl, CONR 11 ,R 12 , CH 2 NR 13 R 14 , phenyl or a 5 or 6-membered heteroaryl group comprising 1-3 heteroatoms selected from O, N and S; each R 8 is independently (C 1-3 )alkyl; R g is H or (C 1-6 )alkyl, optionally subsituted with 1-3 halogens, hydroxyl or COOR 8 ; R 10 is H, (C 1-3 )alkyl or a 5-membered heteroaryl group comprising 1-3 heteroatoms selected from N,S and O; or R 9 and R 10 form together with the nitrogen atom to which they are bonded a saturated 5-7 membered ring; R 11 , R 12 , R 13 and R 14 are independently selected from H or (C 1-3 )alkyl; or a pharmaceutically acceptable salt thereof. W is C(O)NH or NH(CO); Y is CHR 3 or a bond; X is N, CH, CF or CR 8 ; A is a (hetero)aromatic group selected from R 1 is H, halogen, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy or halo(C 1-4 )alkyloxy; R 2 is H, halogen, di(C 1-4 )alkylamino, (C 1-4 )alkyl, (C 2-4 )alkenyl, (C 2-4 )alkynyl, halo(C 1-4 )alkyl or (C 1-6 )alkyloxy, optionally substituted with one or more halogens, hydroxy or (C 1-4 )alkyloxy; or R 2 is OCH 2 R 7 ; R 3 is H, (C 1-3 )alkyl or COOR 8 ; R 4 is H, halogen or (C 1-3 )alkyl; or R 4 forms together with R 3 and the carbon atoms to which they are bonded a (C 3-5 )CyCloalkyl goup; R 5 is, halogen, (C 1-4 )alkyl, halo(C 1-4 )alkyl, hydroxy(C 1-4 )alkyl, CN, COOH, CONR 9 ,R 10 , pyridyl or a 5-membered heteroaryl group comprising 1, 2 or 3 nitrogen atoms and optionally an oxygen or a sulfur atom; R 6 is H, hydroxy or halogen; or R 6 forms together with R 5 and the carbon atoms to which they are bonded a fused 5-membered heteroaryl group comprising 1 or 2 nitrogen atoms and optionally an oxygen or a sulfur atom; R 7 is vinyl, ethynyl, cyano, (C 3-6 )cycloalkyl, CONR 11 ,R 12 , CH 2 NR 13 R 14 , phenyl or a 5 or 6-membered heteroaryl group comprising 1-3 heteroatoms selected from O, N and S; each R 8 is independently (C 1-3 )alkyl; R g is H or (C 1-6 )alkyl, optionally subsituted with 1-3 halogens, hydroxyl or COOR 8 ; R 10 is H, (C 1-3 )alkyl or a 5-membered heteroaryl group comprising 1-3 heteroatoms selected from N,S and O; or R 9 and R 10 form together with the nitrogen atom to which they are bonded a saturated 5-7 membered ring; R 11 , R 12 , R 13 and R 14 are independently selected from H or (C 1-3 )alkyl; or a pharmaceutically acceptable salt thereof. <EOS>